Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid Regurgitation - Trial NCT05497141
Access comprehensive clinical trial information for NCT05497141 through Pure Global AI's free database. This phase not specified trial is sponsored by Xiamen Cardiovascular Hospital, Xiamen University and is currently Recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 98 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System
Interventional
device
Sponsor & Location
Xiamen Cardiovascular Hospital, Xiamen University
Timeline & Enrollment
N/A
Jul 22, 2022
Oct 22, 2023
Primary Outcome
Rate of Implantation Success
Summary
To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve
 edge-to-edge repair system in patients with severe tricuspid regurgitation.
 
 This is a prospective, multicenter, randomized, objective performance criteria trial. 98
 patients who meet the inclusion criteria will be included in the study. This study will be
 conducted in in each site as run-in subjects. Subjects who meet the requirements and who
 voluntarily participate in the trial and sign the informed consent form, will be implanted
 with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05497141
Device Trial